Topic Highlight
Copyright ©The Author(s) 2015.
World J Gastroenterol. Oct 28, 2015; 21(40): 11273-11281
Published online Oct 28, 2015. doi: 10.3748/wjg.v21.i40.11273
Table 1 Vaccines recommended in patients with inflammatory bowel disease
VaccineType of immunogenGeneral recommendations for vaccination in IBDConcerns in IBD patients on immunosuppressive therapy
HBVRecombinant proteinAfter checking the serological status for HBV: double-dose scheduleNone
HPV1Quadrivalent vaccine (Recombinant proteins)Women aged between 11-12 yr: 3 doses (0, 2 and 6 mo)None
InfluenzaInactivated virus1 dose annuallyNone
PneumococcusPolysaccharides, conju-gated or not to a protein carrier1 dose every 5 yrNone
TetanusInactivated toxoidNone
Patient previously vaccinated: 1 dose every 10 years
Unknown or not previously vaccinated: 3-doses
Measles-mumps-rubellaLive attenuated virusNon-immunized: Standard scheduleContraindicated
VaricellaLive attenuated virusNon-immunized: 2 doses (0 and 1-2 mo)Risks and benefits should be evaluated on an individual basis
Herpes zoster1Live attenuated virusPatients aged over 60 yr: Standard scheduleRisks and benefits should be evaluated on an individual basis
Table 2 Vaccines recommended in patients with inflammatory bowel disease and mechanisms associated with impaired response in these patients
VaccineImmunogenImpaired responseFactors associated with a lower responseMechanisms associated with lower immunogenicity
HBVRecombinant proteinYesAge[20,21,23], immunosuppressive or anti-TNF therapy[20,21,23]Not described
HPVRecombinant proteinNo--
InfluenzaInactivated virusYesImmunosuppressive therapy[8]Not described
PneumococcusPolysaccharidesYesImmunosuppressive and/or anti-TNF therapy[9,10,55]Conflicting results about memory B cells[60,62]
TetanusInactivated toxoidUnclearNone describedDefects in the development of IgG-secreting plasma cells[65]
Measles-mump-rubellaLive attenuated virusNo--
VaricellaLive attenuated virusNo--
Herpes zosterLive attenuated virusNo--